International Extranodal Lymphoma Study Group (IELSG)
International Extranodal Lymphoma Study Group (IELSG)
Explore linked clinical trials.11 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm | Active, not recruiting | Not stated | 2026-07-24 | NCT04333524 | |
| Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients | splenic marginal zone lymphoma | Active, not recruiting | Phase 3 | 2026-07-22 | NCT05735834 | |
| Molecular and Cellular Characterization of MALT Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Not stated | 2026-06-22 | NCT07376330 | |
| Characterization of Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL) by Multiomic Approach | Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL) | Not yet recruiting | Not stated | 2026-06-22 | NCT07147751 | |
| Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, nodal marginal zone B-cell lymphoma | Recruiting | Not stated | 2026-06-22 | NCT05700149 | |
| MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm, nodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma | Active, not recruiting | Phase 2 | 2026-04-08 | NCT03697512 | |
| Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma | Lymphoma, Extranodal NK-T-Cell, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, lymphoma, neoplasm | Active, not recruiting | Phase 2 | 2026-04-07 | NCT04417166 | |
| Study of Acalabrutinib and Tafasitamab in MZL Patients | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm | Active, not recruiting | Phase 2 | 2026-04-06 | NCT04646395 | |
| Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma | Transformed Splenic Marginal Zone Lymphoma | Recruiting | Not stated | 2026-01-16 | NCT06712459 | |
| Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-01-15 | NCT01808599 | |
| Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma | Primary Mediastinal B-cell Lymphoma | Active, not recruiting | Not applicable | 2026-01-15 | NCT01599559 |